Mylan (MYL) Earning Somewhat Favorable Media Coverage, Accern Reports
Headlines about Mylan (NASDAQ:MYL) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mylan earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.4456873459222 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s analysis:
- Future Growth of MRSA Drugs Market | Which is Estimated to grow USD 1,393.5 million | Forecast to 2023 (medgadget.com)
- Financial Contrast: Mylan (MYL) versus NephroGenex (NRXGQ) (americanbankingnews.com)
- Mylan, Aspen introduce generic Busulfex injection in US market (pharmabiz.com)
- Mylan To Commercialize Generic Busulfex Injection In U.S. – Quick Facts (rttnews.com)
- Mylan NV – Value Analysis (NASDAQ:MYL) : December 4, 2017 (finance.yahoo.com)
Shares of Mylan (MYL) traded down $0.42 during midday trading on Wednesday, hitting $36.99. 5,680,008 shares of the stock were exchanged, compared to its average volume of 5,950,568. The firm has a market capitalization of $20,084.17, a PE ratio of 7.97, a P/E/G ratio of 2.05 and a beta of 1.38. Mylan has a 52-week low of $29.39 and a 52-week high of $45.87. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95.
A number of equities analysts recently weighed in on MYL shares. Citigroup raised shares of Mylan from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $36.00 to $42.00 in a research note on Wednesday, August 16th. UBS reissued a “buy” rating and set a $46.00 target price (down previously from $50.00) on shares of Mylan in a research note on Thursday, August 10th. Mizuho reissued a “buy” rating and set a $37.00 target price (down previously from $53.00) on shares of Mylan in a research note on Sunday, August 20th. BMO Capital Markets reissued a “buy” rating and set a $45.00 target price on shares of Mylan in a research note on Friday, September 29th. Finally, ValuEngine raised shares of Mylan from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company. Mylan currently has a consensus rating of “Buy” and a consensus price target of $41.49.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.